Curated News
By: NewsRamp Editorial Staff
May 22, 2025
Nutriband Advances Aversa Technology with Kindeva Drug Delivery Partnership
TLDR
- AVERSA Fentanyl is poised to be the first opioid pain patch with abuse deterrent properties, offering a unique advantage in the market.
- Nutriband and Kindeva Drug Delivery have established a comprehensive partnership to develop the Aversa technology for commercialization.
- The development of AVERSA Fentanyl with abuse deterrent properties has the potential to improve pain management and reduce opioid misuse, benefitting society.
- Exciting partnership between Nutriband and Kindeva Drug Delivery aims to revolutionize opioid pain management with innovative technology.
Impact - Why it Matters
This news matters as it signifies a significant step towards creating the world's first opioid pain patch with abuse deterrent properties. The partnership between Nutriband and Kindeva Drug Delivery showcases a dedication to advancing healthcare technology and addressing opioid abuse issues, potentially impacting the future of pain management and drug delivery systems.
Summary
In a recent report to shareholders, Nutriband (NASDAQ: NTRB) CEO Gareth Sheridan highlighted the company's progress in commercializing the Aversa technology, specifically the AVERSA Fentanyl pain patch with abuse deterrent properties. Nutriband has formed a strong partnership with Kindeva Drug Delivery to develop this innovative product, emphasizing a commitment to product development and scaling up manufacturing processes.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Nutriband Advances Aversa Technology with Kindeva Drug Delivery Partnership
